Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Sawyers
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ORIC Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
ORIC is a privately held company focused on discovery and development of novel therapies against treatment-resistant cancers. Dr. Sawyers receives consulting fees from and has equity in ORIC. The sub-aim for Project 001 of this study proposes to use a compound from ORIC in pre-clinical studies in prostate cancer.
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center
PROJECT NARRATIVE 26,000 men die each year in the US from metastatic prostate cancer because the disease develops resistance to the primary treatment, called hormone therapy. DNA sequencing studies of tumors from these patients has revealed new strategies to treat prostate cancer with novel drugs in combination with hormone therapy. This application assembles a team of experts on this topic to work together to test these new therapies in laboratory models of prostate cancer developed directly from patients and identify those that should be accelerated into clinical development.
Filed on August 22, 2018.
Tell us what you know about Charles Sawyers's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charles Sawyers filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Sawyers | Sloan Kettering Inst Can Research | Conflict of Interest | ORIC Pharmaceuticals | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.